These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

414 related items for PubMed ID: 9272340

  • 1. Adverse reactions of a pertussis toxoid vaccine in a double-blind placebo-controlled trial.
    Taranger J, Trollfors B, Knutsson N.
    Dev Biol Stand; 1997; 89():109-12. PubMed ID: 9272340
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Severe adverse events in a comparative efficacy trial in Germany in infants receiving either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) or DT vaccine. The Pertussis Vaccine Study Group.
    Uberall MA, Stehr K, Cherry JD, Heininger U, Schmitt-Grohé S, Laussucq S, Eckhardt T.
    Dev Biol Stand; 1997; 89():83-9. PubMed ID: 9272335
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
    Gustafsson L, Hallander HO, Olin P, Reizenstein E, Storsaeter J.
    N Engl J Med; 1996 Feb 08; 334(6):349-55. PubMed ID: 8538705
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. A comparative efficacy trial in Germany in which infants received either the Lederle/Takeda acellular pertussis component DTP (DTaP) vaccine, the Lederle whole-cell component DTP (DTP) vaccine or DT vaccine.
    Stehr K, Cherry JD.
    Dev Biol Stand; 1997 Feb 08; 89():58-62. PubMed ID: 9333571
    [No Abstract] [Full Text] [Related]

  • 11. Hypotonic hyporesponsive episodes in eight pertussis vaccine studies.
    Heijbel H, Ciofi degli Atti M, Harzer E, Liese J, Preziosi MP, Rasmussen F, Schmitt HJ, Storsaeter J, Taranger J, Uberall M, Tozzi AE.
    Dev Biol Stand; 1997 Feb 08; 89():101-3. PubMed ID: 9272338
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. An adolescent-adult formulation tetanus and diptheria toxoids adsorbed combined with acellular pertussis vaccine has comparable immunogenicity but less reactogenicity in children 4-6 years of age than a pediatric formulation acellular pertussis vaccine and diphtheria and tetanus toxoids adsorbed combined with inactivated poliomyelitis vaccine.
    Langley JM, Predy G, Guasparini R, Law B, Diaz-Mitoma F, Whitstitt P, Tapiero B, Dionne M, Tomovici A, Mills E, Halperin SA.
    Vaccine; 2007 Jan 22; 25(6):1121-5. PubMed ID: 17045366
    [Abstract] [Full Text] [Related]

  • 14. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.
    Halperin SA, King J, Law B, Mills E, Willems P.
    Clin Infect Dis; 1999 May 22; 28(5):995-1001. PubMed ID: 10452624
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. The Gothenburg pertussis vaccine study.
    Trollfors B, Taranger J.
    Dev Biol Stand; 1997 May 22; 89():49-51. PubMed ID: 9333568
    [No Abstract] [Full Text] [Related]

  • 17. Safety and immunogenicity of two acellular pertussis vaccines with different pertussis toxoid and filamentous hemagglutinin content in infants 2-6 months old.
    Halperin SA, Eastwood B, Barreto L, Mills E, Blatter M, Reisinger K, Bader G, Keyserling H, Roberts EA, Guasparini R.
    Scand J Infect Dis; 1995 May 22; 27(3):279-87. PubMed ID: 8539554
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pertussis vaccine effectiveness among children 6 to 59 months of age in the United States, 1998-2001.
    Bisgard KM, Rhodes P, Connelly BL, Bi D, Hahn C, Patrick S, Glodé MP, Ehresmann KR, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. kbisgard@cdc.gov.
    Pediatrics; 2005 Aug 22; 116(2):e285-94. PubMed ID: 16061582
    [Abstract] [Full Text] [Related]

  • 20. Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.
    America Academy of Pediatrics Commitee on Infectious Diseases.
    Pediatrics; 2006 Mar 22; 117(3):965-78. PubMed ID: 16382131
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.